Premature Ovarian Failure: A Critical Condition in The Reproductive Potential with Various Genetic Causes

Farkhondeh Pouresmaeili, Ph.D.1,2*, Zahra Fazeli, M.Sc.1

1. Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2. Infertility and Reproductive Health Research Center (IRHRC), Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract

Premature ovarian failure (POF) is identified as a heterogeneous disorder leading to amenorrhea and ovarian failure before the age of 40 years. The first known symptom of the disease is having irregular menstrual periods. The phenotype appearance of POF depends significantly on the variations in hormones. Low levels of gonadal hormones (estrogens and inhibins) and increased level of gonadotropins [luteinizing hormone (LH) and Follicle stimulating hormone (FSH)] (hypergonadotropic amenorrhea) are well documented as causes of POF. There is an association between the failure of germ cell development and complete ovarian failure, and consistently decreased number of germ cells is more likely associated with partial ovarian failure resulting in secondary amenorrhea. A literature review on recent findings about POF and its association with genomic alterations in terms of genes and chromosomes. POF is a complex heterogeneous disorder. Some of POF cases are carriers of a single gene mutation inherited in an autosomal or X-linked manner while a number of patients suffer from a chromosome abnormality like Turner syndrome in mosaic form and manifest secondary amenorrhea associated with ovarian dysgenesis. Among many of the known involved genes in POF development, several are prove to be positively associated to the disease development in different populations. While there is a promising association between X chromosome anomalies and specific gene mutations with POF, genome-wide analysis could prove a powerful tool for identifying the most important candidate genes that influence POF manifestation.

Keywords: Premature Ovarian Failure, Infertility, Amenorrhea

Introduction

Premature ovarian failure (POF [MIM 311360]) is an early ovarian malfunction different from menopause, which disturbs production of follicles resulting in amenorrhea under the age of 40 in 1-3% of reproductive age women (1-3). About 10-28% of the patients experience primary amenorrhea and about 4-18% show secondary Amenorrhea (2). Affected women show menstrual problems followed by an elevated level of gonadotropines [follicle stimulating hormone (FSH) ≥40IU/L] and hypoesestrogenism for an average four months (4). Measuring serum FSH is a routine diagnosis procedure for the disease (2, 5). Genetic analysis of the early menopause patients showed that a variety of gene defects and chromosome anomalies involving X chromosome and autosomes were associated with POF. The studies confirmed that...
the multifactorial and heterogeneous biological events including infection, autoimmune disorders and metabolic factors are likely responsible for the disorder development. In 90% of observed cases, the etiology is unknown and the disease is defined as idiopathic POF (2, 6-8).

Most POF cases are sporadic and it is suggested that between 4-31% of them are familial (9-11). In this regard, the abnormalities of the X chromosome are presented as the most important causes of the disease (12-17), followed by the fragile X mental retardation (FMR1) pre-mutation which is present in POF patients with frequencies of 13 and 6%, respectively (18, 19).

Loss of one X chromosome as X monosomy [Turner syndrome (TS)], the related gene deletions and X/autosome translocations, trisomy X, X linked gene mutations and premutations and abnormalities of autosomal linked genes have been widely studied in correlation with POF disease. In examining the genetic mutations responsible for POF, each mutation could affect part of the disease phenotype. The diagnosis of the disease could be confirmed by two separate blood tests for FSH (4). Studies in different populations have shown various factors in association with POF. In addition to the genetic anomalies and chromatin structure of specific genome environment, autoimmune factors and toxins are reported as other important causes of the disease. The exact reason for POF development still remains unknown in many cases.

Cytogenetic analysis for POF

Chromosome abnormalities

In different reports, chromosomal abnormalities have been recognized as the most common causes of POF disease (12-17, 20), confirming the importance of cytogenetic analysis in reproductive management and genetic counseling for this disease. Investigations in this regard show the association of POF with chromosome abnormalities, particularly those of X chromosome such as structural anomalies, translocation of X with autosomes, isochromosomes and the related aneuploides (21-25). Also, translocation of Y chromosome heterochromatic regions on derivative X chromosome which affected the X chromosome inactivation was reported (26). Presence of a Y chromosome in a woman’s genome is a clear sign of chromosome abnormality which mostly causes tumor formation in mosaic karyotypes. Pouresmaeili et al. reported a patient with POF who carried aneuploidy of this kind (27). Unknown X-linked gene imbalance is an expected cause of POF in these patients.

A critical region from Xq13.3 to Xq27 has been characterized for ovarian development and function (28). Studies have shown that deletion of the short arm and the long arm of the X chromosome result in either early primary or secondary amenorrhea (29). These observations suggested that important genes for normal ovarian function are located on both arms of the X chromosome (30).

Translocational studies between X chromosome and autosomes have been significant in determining the involvement of autosomal as well as X chromosomal genes in the development of POF disease. For example, the association of HS6ST1, HS6ST2, MATER and CHM genes with POF were identified following to the analysis of the POF patients with karyotypes 46, X, der (X) t (X; 19) (p21; q13), 46, X, t (X; 2) (q21; q14), 46, X, der (X)t (X; Y) (q25-26; q11.22), 46, X, t (X; 4) (q21.2; p16.3) respectively (31, 32). One possible explanation for the disease occurrence in these cases was attributed to the positional effect of an autosome-X chromosome translocation. In fact, transferred genes to the highly heterochromatic region of the X chromosome tolerate epigenetic effects after a rearrangement which changes their chromatin structure and consequently result in lower expression of genes associated with ovarian function and fertility (33).

Moreover, some studies have reported a Robertsonian translocation (13, 14) in some women with sporadic POF. It was also suggested that the functional changes and interruptions in some critical genes for ovarian function on acrocentric chromosomes, due to translocation, could be a possible reason of the disease etiology in this group of patients (20, 34, 35).

Also, there are POF patients with trisomy X who were diagnosed after showing an endocrine disorder, hypergonadotropic hypogonadism (36). It is suggested that the genes located on the X chromosome escaping inactivation could be overexpressed in 47, XXX patients, resulting in the disorder revelation (37). It is identified that complete
POF Genetics

absence or a segmental deletion of one X chromosome (TS) causes abnormalities throughout the reproductive system. Using fluorescent in situ hybridization (FISH) and several specific markers to the short arm of X chromosome including DXS1058, DXS6810, DXS1302 and ZXDB, deletion of Xp11.2-p22.1 was introduced as a critical area related to TS and POF (38). Therefore, we understand that the presence of two intact X chromosomes is indigence vital for normal ovarian function (8, 39-41) and prevents follicle apoptosis and atresia (41). This hypothesis is supportive for the POF etiology when there is a significant difference between the highest and lowest follicle numbers in mosaic Turner syndrome and subjects with 45, X karyotype (42).

Trisomy X with or without Turner’s syndrome

Chromosome aneuploidy leading to trisomy X is known as one of the genetic reasons of POF which causes elevated endocrine gonadotropine hormone (FSH) with an incidence rate of 1:1000 female live births. Although the ovarian function is normal in most of trisomy X patients, but the ovarian dysfunction in some 47, XXX might manifest as early menopause, secondary amenorrhea and oligomenorrhea (36).

Mosaic types of the syndrome include 10% of the cases with various karyotypes such as 46, XX/47, XXX or 45, X/47, XXX. The mosaic trisomy X might be the result of a post-zygotic non-disjunction event or post-zygotic trisomy rescue. The manifestation of symptoms depends on the time at which the causing events occurred.

The cytogenetic analysis done on POF patients indicated that trisomy X (regardless of mosaic or non-mosaic) have low frequency in individuals with POF (30, 37, 43).

The patients carried different symptoms with abnormalities in genitourinary tract which could be associated with the trisomy status (44). Although some of the cases showed uterine dysgenesis, other cases had no defects in the reproductive system and sexual development (37).

Investigations have shown that the autoimmune thyroid disease is related to many POF cases with trisomy X (45). The ovarian failure in 47, XXX patients (either mosaic or non-mosaic) could be the result of meiotic disorganization of three X chromosomes (20). However, more studies on 47, XXX patients with POF are required.

POF and gene mutations

Numerous studies have identified different genes whose functions were significant in ovarian development and also play a role in POF progression. However, inconsistent results have been observed in different studies which are presumably the result of genetic variability between studied ethnic groups (46-48). Table 1 describes several candidate genes with possible involvement in ovarian function and POF genesis. All the introduced genetic variation as mutations and polymorphisms are thought to affect POF (30).

The FMR1 premutation of CGG repeats with incidence of 1:800 in males and 1:100-200 in women is recognized as the most important gene associated with POF (49-51). The authors mention that carrier women of the premutation are predisposed to POF disease. Expression study on fragile X mental retardation protein has demonstrated that the variation in the level of the gene product (FMRP) could be utilized as a candidate biomarker to evaluate a person with folliculogenesis disruption, heavy follicle atresia and eventual POF. In this study immunocytochemistry was applied on ovarian sections to show different FMRP1 signals in tissues with different CGG repeats. These expression studies showed that the elevated amount of the expressed gene in fetus germ line cells have a negative effect on the number of oocytes and their development (52, 53). The incidence of the disease is about 0.1-1% in normal individuals but 20-28% in the carriers of premutation FMR1, 13 times more than controls, respectively (54-58). Some studies indicated that the intermediate alleles of FMR1 CGG repeats could also increase the risk of POF development (57, 59-66).

SF1, a nuclear receptor which is expressed in various cell types in fetus and adult, regulates different genes involved in development of the reproductive system, hypothalamic-pituitary-steroidogenesis and familial or isolated POF. The gene polymorphism Gly146Ala resulted from GGG to GCG sequence is known to be associated with POF in either familial or isolated form. Carriers of the 146Ala allele showed a significant decline in plasma stradiol. Therefore, this polymorphism could be a risk marker for POF in some women (67-72).
Table 1: Some candidate genes with positive influence on ovarian development and function

| Gene                          | Chromosome location | The function of gene in association with POF                                                                 | Reference                                                                                   |
|-------------------------------|---------------------|-----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
| FMR1                          | Xq27.3              | Oocyte development and number of oocytes                                                                  | Allen et al. 2007 (53)                                                                      |
| SF1                           | 11q13               | Regulation of gonadal sexual differentiation, follicular maturation and regulation of ovarian steroidogenesis | Lakhal et al. (2012), Ikeda et al. (1994), Leers-Sucheta et al. (1997), Jeyasuria et al. (2004), Reinhart et al. (1999), Luo et al. (1994) (67-72) |
| INHA (Inhibin-alpha)          | 2q33-36             | Folliculogenesis                                                                                         | Shelling et al. (2000), Chand et al. (2010) (73, 74)                                        |
| LHR (Luteinizing hormone receptor) | 2p21               | Follicular growth and oocyte maturation                                                                  | Pakarainen et al. (2005) (78)                                                              |
| FSHR (Follicle stimulating hormone receptor) | 2p21               | Follicular development                                                                                    | Ohkubo et al. (2013), Wei et al. (2013) (82, 83)                                             |
| FOXL2                         | 3q23                | Ovarian follicle development                                                                             | Uhlenhaut and Treier, (2006), Pisarska et al. (2004), Schmidt et al. (2004), Mu et al. (2013) (89-92) |
| FOXO3a                        | 6q21                | Regulatory role in follicular activation                                                                | Watkins et al. (2006) (98)                                                                 |
| ER (Estrogen Receptor)        | 6q25                | Regulation of folliculogenesis                                                                           | Kolibianakis et al. (2005) (100)                                                           |
| CYP19A1                       | 15q21.1             | Regulation of folliculogenesis through epistatic interaction with ESR1 gene; Ovary differentiation       | Duffy et al. (2010), Kohno et al. (2010), Kim et al. (2011) (108-110)                         |
| CXCL12 (Chemokine)            | 10q11.1             | Primordial germ cell migration, colonization and survival, primordial to primary follicle transition     | Doitsidou et al. (2002), Knaut et al. (2003), Molyneaux et al. (2003), Stebler et al. (2004), Herpin et al. (2008) (111-115) |
| FMR2                          | Xq28                | Unknown                                                                                                  | Murray et al. (1999) (118)                                                                 |
| NOBOX                         | 7q25                | Early folliculogenesis                                                                                    | Rajkovic et al. (2004) (119)                                                               |
| DIAPH2                        | Xq22                | The ovarian follicular development                                                                       | Bione et al. (1998), Mandon-Pépin et al. (2003) (124, 125)                                  |
| MTHFR (Methylenetetrahydrofolate reductase) | 1p36.3             | Folliculogenesis                                                                                         | Laanpere et al. (2010) (127)                                                              |
| LAMC1 (Laminin gamma 1 gene)  | 1q31                | High expression during ovulation                                                                         | Pyun et al. (2012) (132)                                                                  |
Inhibins are of other POF candidate genes predominantly produced in the ovary at different times of the menstrual cycle and play a regulatory role in folliculogenesis (73, 74). Among these proteins, Inhibin alpha (INHA) gene polymorphisms have been shown to have a significant association with risk of POF in certain ethnic populations (74-77).

The luteinizing hormone (LH) through luteinizing hormone receptor (LHR) plays an important role in the follicular growth and oocyte maturation. Women carrying LHR mutations showed anovulation and primary amenorrhea (78-81).

FSH receptor (FSHR) is expressed in the granulosa cells of the ovary and has an important function in follicular development (82, 83). In different studies on Chinese, Argentinian and British women, it has been revealed that FSH receptor gene mutations are seldom identified in POF patients. First, mutations of FSHR and later sentences are talking about them FSHR gene polymorphisms which are different terms (84-88).

FOXL2 was found in undifferentiated granulosa cells of the ovary which are involved in ovarian follicle development (89-92). The studies have indicated that FOXL2 mutations are rarely associated with POF disease (93-95).

The FOX3a is also expressed in the ovary with a regulatory role in the follicular activation (96). Although some mutations of the encoding gene have been reported in women with POF, it seems that FOX3a mutations could not be counted as a common cause (97-99).

Estrogen stimulates gonadotrophins releasing at the hypothalamus-hypophysis-ovarian axis by acting on estrogen receptor-α (ESR1) which enhances folliculogenesis (100). It has been reported that several single nucleotide polymorphisms (SNPs) such as rs2234693, rs9340799 and rs2234693 of ESR1 are associated with the increased risk of POF (101-104). Some studies have suggested an association between Estrogen receptor alpha gene polymorphism, PvuII and XbaI restriction fragment length polymorphisms (RFLPs) and low bone mineral density (BMD) (105), while others observed no significant correlation between these polymorphisms with age, menopausal status and BMD (106). Nevertheless, it has been revealed that baseline BMD and change in menstrual status contributed more to the magnitude of the difference in bone change (107).

The CYP19A1 gene encodes aromatase, the key enzyme in biosynthesis of estrogens. High expression of aromatase during the ovary differentiation has been reported previously (108, 109). Investigations on Korean patients with POF have shown a significant association between 3’ UTR SNPs "rs10046" and "rs4646" of CYP19A1 with the disease (110).

It has been demonstrated that CXCL12 through its receptor acts on migration and survival of primordial germ cells (PGCs) (111-115). The association between CXCL12 polymorphisms and POF has been observed in the studied populations (116, 117).

The FMR2 gene is another candidate gene for POF manifestation. Microdeletions within FMR2 have been found in some individuals with POF disease. However, the function of FMR2 in oocyte development is still unclear (30, 118).

The newborn ovary homeobox gene (NOBOX) functions as an oocyte-specific gene in early folliculogenesis (119). However, the mutation analysis of NOBOX indicated that NOBOX mutations are an uncommon cause of POF (120-122).

In some POF patients, deletions within DIAPH2 have been found along with the breakpoints at Xq22 (123). Researchers believe that the human DIAPH2 influences the ovarian follicular development (124, 125) and that the gene is a potential candidate for POF manifestation (126).

The variants of methylenetetrahydrofolate reductase (MTHFR) gene are evidenced to be associated with folliculogenesis (127). The MTHFR C677T and A1298C polymorphisms are significantly associated with the elevated risk of POF in different studied populations (128, 129).

Laminin is one of the most abundant components of the basal lamina. It has been demonstrated that the LAMC1 expression increases during follicular development (130, 131). LAMC1 variations presented a significantly association with susceptibility to POF (132).

Other genetic variations associated to POF in addition to the discussed genes in table 1, is much
evidence confirming the involvement of other genes coding for small RNAs (like miRNA) during folliculogenesis (133-137). The exact function of these miRNAs is not clear yet, but germ cell development and maturation is influenced by several small RNAs such as piRNA, and siRNA that are supposed to be effective in oocyte maturation (138). The experiments indicated that the mutations or alterations of the involved genes in miRNA processing, biosynthesis or miRNA targets could result in increased susceptibility to sex reversal or infertility (139-143). This effectiveness depends on the gonadotropin hormone surge (like LH and FSH) and the pathway where a gene is able to diminish or elevate another specific activity of a gene in a certain developmental time and in a specific gonad or specific tissue during embryogenesis or ovarian development (144, 145).

In the recent years, copy number variation array (CNV array) has been an effective tool to assess the numerical variation (micro-deletion and micro-duplication) of important genes in early menopause (146). It is believed that chromosomal alterations could negatively affect germ cell apoptosis through meiotic DNA repair disruption (147).

SNPs are genetic variations which in interaction with other genes are thought to increase the risk for premature ovarian failure (148). The association data obtained from analysis of TGFβ3, HSD17B4, LAMC1, ESR1, HK3 and BRSK1 are of the recent studies explaining how gene variants could be correlated to the etiology of premature ovarian failure (117, 132, 149).

Diagnosis and treatment

A woman is diagnosed for POF if she has lost her regular menstrual periods for at least 4 months before the age 40. The reduction of antral follicle in POF patients could be examined by Pelvic ultrasonography (150). A new diagnostic method is the measurement of anti-Mullerian hormone (AMH) produced by antral follicles. The AMH secretion is decreased in POF patients (151, 152). The measurement of anti-adrenal, anti-ovarian and anti-thyroid autoantibodies could be useful in the diagnosis of the immune system deficiency leading to POF (150, 153). After confirming the diagnosis of POF, karyotyping and analysis of FMR1 premutation should be done to exclude major genetic causes (150). The hormone replacement therapy (HRT) is the accepted management for POF patients. Estrogen replacement is recommended to decrease the risk of osteoporosis and cardiovascular disease (154). Anxiety and depression increases in women with POF, thus, psychological support could be useful in the management of the disease (155, 156). POF is associated with complete follicular depletion and infertility. Infertility in patients with POF could be resolved by ovum donation (157). Recent studies have focused on stem cell therapy of POF. One of these investigations used CD44+/CD105+ HuAFCs (human amniotic fluid cells) to treat POF in mice and demonstrated that the cells were valid candidates for stem cell transplantation of POF due to their long half-life in vitro and mesenchymal potential (158).

Conclusion

Premature ovarian failure is a complicated disorder which inhibits women’s fertility potential years before normal menopause. Most of the cases are idiopathic. Genetic variation, aberrant interaction between genes, autoimmune ovarian atrophy, iatrogenic factors, radiotherapy or chemotherapy, various environmental factors like viruses, toxins and smoking are recognized as the important agents affecting POF.

Women may encounter POF from the time of menarche and before having babies to the final years of their 30s. Many genes are found to be associated with the development, formation and function of the female reproductive system. Polymorphisms of these genes are likely to be used for the diagnosis of POF in women with normal karyotypes. What could be useful for screening and early diagnosis of mutations in these genes is the study of the association of gene polymorphisms in a large population of patients and a deeper scan of the genome including entire exons, introns and regulatory upstream and downstream regions, 5'UTR and 3'UTR regions.

Fortunately, it is easy to collect a large number of patients for testing candidate genes due to
the considerable frequency of POF among fertile women (1%). Technology for mutation screening is also improving rapidly, and it will be feasible to screen a large set of candidate genes rapidly in the near future.

It is difficult to find a single candidate gene for a complex disease. Identification of the role of some important genes in POF etiology is laborious due to their involvement in several biological functions. One of these genes encodes the estrogen receptor, a nuclear factor involved in the pathogenesis of several diseases such as lung cancer, bladder cancer, osteoporosis as well as its critical role in sexual development and reproductive organization (106, 159-161). Certainly, screening a group of the genes involved in creating POF becomes easier in the future. Genetic analysis through genome-wide tests using microarray technology may identify candidate genes in patients with POF. This kind of information is helpful and informative for genetic counseling and risk assessment of POF susceptibility in family members of a particular patient.

There are conflicting data about association between some gene variants with POF, suggesting the effectiveness of interactions between haplotypes of different genes on the disease etiology (75, 76, 162). A variety of analytical tools such as genome-wide association study (GWAS) could be used to find genetic variations associated with the disease (163). Another well-known and useful method is linkage analysis which can find the defective chromosomal haplotype associated with POF etiology of non-syndromic POF (164).

It is helpful to screen women at risk for POF in early age to preserve their fertility with newly available technologies. Based on the present information, the study of X chromosome abnormalities is the easiest way to look at the immediate genetic cause of POF. Surely, after the identification of POF associated genes in the future, easier and cheaper genetic tests for early diagnosis of POF will improve the livelihood of women.

Acknowledgements

We greatly appreciate our colleagues for reading the manuscript. There is no conflict of interest in this study.

References

1. Nelson LM, Covington SN, Rebar RW. An update: spontaneous premature ovarian failure is not an early menopause. Fertil Steril. 2005; 83(5): 1327-1332.
2. Goswami D, Conway GS. Premature ovarian failure. Hum Reprod Update. 2005; 11(4): 391-410.
3. Santoro N. Mechanisms of premature ovarian failure. Ann Endocrinol(paris). 2003; 64(2): 87-92.
4. Goswami D, Conway GS. Premature ovarian failure. Horm Res. 2007; 68(4): 196-202.
5. Welt CK. Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin Endocrinol (Oxf). 2008; 68(4): 499-509.
6. Vujovic S. Aetiology of premature ovarian failure. Menopause. 2009; 15(2): 72-75.
7. Shelling AN. Premature ovarian failure. Reproduction. 2010; 140(5): 633-641.
8. Lami T, Preyer O, Umek W, Hengstschlager M, Hanzl H. Genetic disorders in premature ovarian failure. Hum Reprod Update. 2002; 8(5): 483-491.
9. Cramer DW, Xu H, Harlow BL. Family history as a predictor of early menopause. Fertil Steril. 1995; 64(4): 740-745.
10. Torgerson DJ, Thomas RE, Reid DM. Mothers and daughters menopausal ages: is there a link?. Eur J Obstet Gynecol Reprod Biol. 1997; 74(1): 63-66.
11. Vegetti W, Grazia Tilibetti M, Testa G, de Lauretis Yankowski, Alagna F, Castoldi E, et al. Inheritance in idiopathic premature ovarian failure: analysis of 71 cases. Hum Reprod. 1998; 13(7): 1796-1800.
12. Castillo S, Lopez F, Tobella L, Salazar S, Daher V. The cytogenetics of premature ovarian failure. Rev Chil Obstet Ginecol. 1992; 57(5): 341-345.
13. Portnoi MF, Aboura A, Tachdjian G, Bouchard P, Dewailly D, Bourcigaux N, et al. Molecular cytogenetic studies of Xq critical regions in premature ovarian failure patients. Hum Reprod. 2006; 21(9): 2329-2334.
14. Ceylaner G, Altinkaya SO, Mollamahmutoglu L, Ceylaner S. Genetic abnormalities in Turkish women with premature ovarian failure. Int J Gynaecol Obstet. 2010; 110(2): 122-124.
15. Janse F, Knauff EA, Niermeijer MF, Eijkemans MJ, Laven JS, Lambalk CB, et al. Similar phenotype characteristics comparing familial and sporadic premature ovarian failure. Menopause. 2010; 17(4): 759-765.
16. Lakhal B, Braham R, Berguigua R, Bouali N, Zauouali M, Chaieb M, et al. Cytogenetic analyses of premature ovarian failure using karyotyping and interphase fluorescence in situ hybridization (FISH) in a group of 1000 patients. Clin Genet. 2010; 78 (2): 181-185.
17. Baronchelli S, Conconi D, Panzeri E, Bentivegna A, Redaelli S, Lisoni S, et al. Cytogenetics of premature ovarian failure: an investigation on 269 affected women. J Biomed Biotechnol. 2011; 2011: 370195.
18. Conway GS, Hettiarachchi S, Murray A, Jacobs PA. Fragile X premutations in familial premature ovarian failure. Lancet. 1995; 346(8970): 309-310.
19. Sherman SL. Premature ovarian failure in the fragile X syndrome. Am J Med Genet. 2000; 97(3): 189-194.
20. Jiao X, Qin C, Li J, Qin Y, Gao X, Zhang B, et al. Cytogenetic analysis of 531 Chinese women with premature ovarian failure. Hum Reprod. 2012; 27(7): 2201-2207.
21. Devi A, Benn PA. X-chromosome abnormalities in wom-
en with premature ovarian failure. J Reprod Med. 1999; 44(4): 321-324.
22. Schlessinger D, Herrera L, Crisponi L, Mumm S, Pers-
cesepe A, Pellegrini M, et al. Genes and translations
involved in POF. Am J Med Genet. 2002; 111(3): 328-333.
23. Toniole D, Rizzolio F, X chromosome and ovarian failure.
Semin Reprod Med. 2007; 25(4): 264-271.
24. Bertini V, Ghiri P, Bicocchi MP, Simi P, Valetto A. Molecu-
lar cyogenetic definition of a translocation t(X;15) asso-
ciated with premature ovarian failure. Fertil Steril. 2010;
93(3): 1097.e5-6.
25. Saranya B, Kavitha D, Chandra RS, Jayashankar M,
Santhiya ST. Translocation t(X;11) (q22;q25) in a woman
with premature ovarian failure. Sex Dev. 2013; 7(4): 216-221.
26. Cheng DH, Tan YQ, Di YF, Li LY, Lu GX. Crypt Y chromo-
some fragment resulting from an X;Y translocation in a
patient with premature ovarian failure. Fertil Steril. 2009;
92(2): 828.e 3-6.
27. Pouresmaeili F, Fallahian M, Azizi F, Azargashb E, Arian
N, Shirafkan A, et al. Chromosomal abnormalities in wom-
en with premature ovarian failure. J Reprod Fertil. 2007;
8(2): 142-148.
28. Persani L, Rossetti R, Cacciatore C, Bonomi M. Primary
ovarian insufficiency: X chromosome defects and autoim-
munity. J Autoimmun. 2006; 31(1): 35-41.
29. Sybert VR, McCauley E. Turner’s syndrome. N Engl J
Med. 2004; 351(12): 1227-1238.
30. Cordts EB, Christofolini DM, Dos Santos AA, Bianco B,
Barbosa CP. Genetic aspects of premature ovarian failure:
a literature review. Arch Gynecol Obstet. 2011, 283(3):
635-643.
31. Baronchelli S, Villa N, Redaelli S, Lissoni S, Saccheri
P, Panzera E, et al. Investigating the role of X chromosome
breakpoints in premature ovarian failure. Mol Cytogenet.
2012; 5(2): 68-77.
32. Lorda-Sanchez UJ, Ibáñez AJ, Sanz RJ, Trujillo MJ, Ana-
bartite ME, Querejeta ME, et al. Choroideremia, sensori-
near deafness, and primary ovarian failure in a woman
with a balanced X-4 translocation. Ophthalmic Genet.
2000; 21(3): 185-189.
33. Rizzolio F, Pramparo T, Sala C, Zuffardi O, Santisi LD, Ra-
bellotti E, et al. Epigenetic analysis of the critical region I
for premature ovarian failure: demonstration of a highly
heterochromatic domain on the long arm of the mamma-
lian X chromosome. J Med Genet. 2009; 46(9): 589-592.
34. Kopakka N, Dalvi R, Shetty DL, Das BR, Mandava S. Bal-
anced autosomal translocation and double Robertsonian
translocation in cases of primary amenorrhea in an Indian
population. Int J Gynaecol Obstet. 2012; 116(3): 253-257.
35. Hosseini S, Vahid Dastjerdi M, Asgari Z, Samiee H. Pre-
mature ovarian failure in a woman with a balanced 15;21
translocation: a case report. J Med Case Rep. 2011; 5:
250.
36. Holland CM. 47, XXX in an adolescent with premature
ovarian failure and autoimmune disease. J Pediatr Ado-
lesc Gynecol. 2001, 14(2): 77-80.
37. Tartaglia NR, Howell S, Sutherland A, Wilson R, Wilson
L. A review of trisomy X (47, XXX). Orphanet J Rare Dis.
2010; 5(1): 8.
38. Zinn AR, Tonk VS, Chen Z, Flejter WL, Gardner HA, Guer-
ra R, et al. Evidence for a Turner syndrome locus or loci at
Xp11.2-p22.1. Am J Hum Genet. 1998, 63(6): 1577-1566.
39. Davison RM, Davis CJ, Conway GS. The X chromosome
and ovarian failure. Clin Endocrinol. 1999; 51(6): 673-679.
40. Conway GS. Premature ovarian failure. Br Med Bull.
2002; 59(3): 643-649.
41. Zinn AR. The X chromosome and the ovary. J Soc Gy-
necol Investig. 2001; 8 Suppl Proceedings 1: S34-S36
42. Heirnsson JG, Orla M, Friststårom M, Borgström B, Rasm-
ussen C, Lundqvist M, et al. Follicles are found in the
ovaries of adolescent girls with Turner’s syndrome. J Clin
Endocrinol Metab. 2002, 87(8): 3618-3623.
43. Villanueva AL, Rebar RW. Triple-X syndrome and prema-
ture ovarian failure. Obstet Gynecol. 1983; 62 Suppl 3:
70s-73s.
44. Lin HJ, Nidforsch F, Patell S. Exstrophy of the cloaca in
a 47, XXX child: review of genitourinary malformations in
triple-X patients. Am J Med Genet. 1993; 45(6): 761-763.
45. Goswami R, Goewami D, Kato M, Gupta A, Dubey S,
Dadhwal V. Prevalence of the triple X syndrome in phe-
notypically normal women with premature ovarian failure
and its association with autoimmune thyroid disorders.
Fertil Steril. 2003; 80(4): 1052-1054.
46. Burchard EG, Ziv E, Coyle N, Gomez SL, Tang H, Karter
AJ, et al. The importance of race and ethnic background
in biomedical research and clinical practice. N Engl J Med.
2003; 348(11): 1170-1175.
47. Sundblad V, Chiauzzi VA, Andreone L, Campo S, Charn-
eau EH, Dain L. Controversial role of inhibin alpha-subu-
nit gene in the aetiology of premature ovarian failure. Hum
Reprod. 2006; 21(5): 1154-1160.
48. Marozzi A, Porta C, Vegetti W, Crosignani PG, Tibiletti
MG, Dalprà L, Ginetti E. Mutation analysis of the inhibin
alpha gene in a cohort of Italian women affected by ovar-
ian failure. Hum Reprod. 2002; 17: 1741-1745.
49. Gleicher N, Weghofer A, Barad DH. A pilot study of pre-
mature ovarian senescence: I. Correlation of triple CGG
repeats on the FMR1 gene to ovarian reserve parameters
FSH and anti-Mullerian hormone. Fertil Steril. 2009; 91
(5): 1700-1706.
50. Dombrowski C, Lévesque S, Morel ML, Rouillard P, Mor-
gan K, Rousseau F. Premutation and Intermediate-size
FMR1 alleles in 10572 females from the general popula-
tion: loss of an AGG interruption is a late event in the gener-
ation of fragile X syndrome alleles. Hum Mol Genet. 2002;
11(4): 371-378.
51. Rousseau F, Rouillard P, Morel ML, Khandjian EW, Morgan
K. Prevalence of carriers of premutation-size alleles of the
FMR1 gene--and implications for the population genet-
ic of the fragile X syndrome. Am J Hum Genet. 1995;
57(5): 1006-1018.
52. Schuettler J, Peng Z, Zimmer J, Sinn P, von Hagens C,
Strowitzki T, Vöglt PH. Variable expression of the Fragile X
Mental Retardation 1 (FMR1) gene in patients with prema-
ture ovarian failure syndrome is not dependent on number
of (CGG)n triplets in exons 1. Hum Reprod. 2011; 26 (5):
1241-1251.
53. Allen EG, Sullivan AK, Marcus M, Small C, Domínguez C,
Epstein MP et al. Examination of reproductive aging mile-
stones among women who carry the FMR1 premutation.
Hum Reprod. 2007; 22: 2142-2152.
54. Hagerman RJ, Leavitt BR, Farzinn F, Jacquemont S, Greco
CM, Brunberg JA, et al. Fragile-X-associated tremor/atax-
ia syndrome (FXTAS) in females with the FMR1 premuta-
tion. Am J Hum Genet. 2004; 75: 412-421.
55. Corrigan EC, Raygada MJ, Vanderhoof VH, Nelson LM. A
woman with spontaneous premature ovarian failure gives
birth to a child with fragile X syndrome. Fertil Steril. 2005;
84(5): 1508.
56. Lin YS, Yang ML. Familial premature ovarian failure in fe-
male premutated carriers of fragile X syndrome: a case
report and literature review. Taiwan J Obstet Gynecol.
2006; 45(1): 60-63.
57. Sullivan AK, Epstein MP, Allen EG, Anido AE, Pauoin JJ,
et al. Association of FMR1 repeat size with
Int J Fertil Steril, Vol 8, No 1, Apr-Jun 2014 8
ovarian dysfunction. Hum Reprod. 2005; 20(2): 402-412.

58. Vilodre LC, Moreto M, Kohek MB, Spritzer PM. Premature ovarian failure: present aspects. Arq Bras Endocrinol Metabol. 2007; 51(6): 920-929.

59. Bodega B, Bione S, Dalprà L, Toniolo D, Ornaghi F, Vegtii W, et al. Influence of intermediate and uninterrupted FMR1 CGG expansions in premature ovarian failure manifestation. Hum Reprod. 2006; 21(4): 952-957.

60. Bretherick KL, Flucker MR, Robinson WP. FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure. Hum Genet. 2005; 117(4): 376-382.

61. Gleichner N, Weghofer A, Oktay K, Barad D. Relevance of triple CGG repeats in the FMR1 gene to ovarian reserve. Reprod Biomed Online. 2009; 19(3): 385-390.

62. Gleichner N, Weghofer A, Oktay K, Barad DH. Correlation of triple repeats on the FMR1 (fragile x) gene to ovarian reserve: a new infertility test?. Acta Obstet Gynecol Scand. 2009; 88(9): 1024-1030.

63. Karimov CB, Moragianvi NA, Cronister A, Srouji S, Petrozza J, Racovsky C, et al. Increased frequency of oc cult fragile X-associated primary ovarian insufficiency in infertile women with evidence of impaired ovarian function. Hum Reprod. 2011; 26(8): 2077-2083.

64. Livshyts AB, Kravchenko SA, Berestovoy A, Zinchenko VA, Chand AL, Harrison CA, Shelling AN. Inhibin and premature ovarian failure. Hum Reprod. 2000; 15(12): 2644-2648.

65. Shelling AN, Burton KA, Chand AL, van Ee CC, France JT, Farquhar CM, et al. Inhibin: a candidate gene for premature ovarian failure. Hum Reprod. 2000; 15(12): 2644-2648.

66. Chand AL, Harrison CA, Shelling AN. Inhibin and premature ovarian failure. Hum Reprod Update. 2010; 16(1): 39-50.

67. Kim H, Chun S, Gu BS, Ku SY, Kim SH, Kim JG. Relationship between inhibin-α gene polymorphisms and premature ovarian failure in Korean women. Menopause. 2011; 18(11): 1232-1236.

68. Woad KJ, Pearson SM, Harris SE, Gersak K, Shelling AN. Investigating the association between inhibin alpha gene promoter polymorphisms and premature ovarian failure. Fertil Steril. 2009; 91(1): 62-66.

Premature Ovarian Failure Genetics

69. Chand AL, Ooi GT, Harrison CA, Shelling AN, Robertson DM. Functional analysis of the human inhibin alpha subunit variant A287T and its potential role in premature ovarian failure. Hum Reprod. 2007; 22(12): 3241-3248.

70. Pakarainen T, Zhang FP, Nurmi L, Poutanen M, Huhtanen M, I. Knockout of luteinizing hormone receptor abolishes the effects of follicle-stimulating hormone on preovulatory maturation and ovulation of mouse graafian follicles. Mol Endocrinol. 2005; 19(10): 2591-2602.

71. Simpson JL. Genetic and phenotypic heterogeneity in ovarian failure: overview of selected candidate genes. Ann N Y Acad Sci. 2008; 1135: 146-154.

72. Toledo SP, Brunner HG, Kraaij R, Post M, Daha PL, Hayashida CY, et al. An inactivating mutation of the luteinizing hormone receptor causes amenorrhea in a 46, XX female. J Clin Endocrinol Metab. 1996; 81(11): 3850-3854.

73. Puett D, Angelova K, da Costa MR, Warrenfeltz SW, Fanelli F. The luteinizing hormone receptor: insights into structure-function relationships and hormone-receptor mediated changes in gene expression in ovarian cancer cells. Mol Cell Endocrinol. 2010; 329(1-2): 47-55.

74. Ohkubo M, Yabu T, Yamashita M, Shimizu A. Molecular cloning of two gonadotropin receptors in mummichog Fundulus heteroclitus and their gene expression during follicular development and maturation. Gen Comp Endocrinol. 2013; 184: 75-86.

75. Wei S, Chen S, Gong Z, Ouyang X, An L, Xie K, et al. Alaralin active immunization influences expression levels of GnRHR, FSHR and LHR proteins in the ovary and enhances follicular development in ewes. Anim Sci J. 2013; 84(6): 466-475.

76. Conway GS, Conway E, Walker C, Hoppner W, Gromoll J, Simoni M. Mutation screening and isoform prevalence of the follicle stimulating hormone receptor gene in women with premature ovarian failure, resistant ovary syndrome and polycystic ovary syndrome. Clin Endocrinol (Oxf). 1999; 51(1): 97-99.

77. Sundblad V, Chiauzzi VA, Escobar ME, Dain L, Charreau EH. Screening of FSH receptor gene in Argentine women with premature ovarian failure, resistant ovary syndrome and high end of the normal range for FSH. Fertil Steril. 2001; 75(3): 535-539.

78. Constaneda I. Knockout of luteinizing hormone receptor abolishes the effects of follicle-stimulating hormone on preovulatory maturation and ovulation of mouse graafian follicles. Mol Endocrinol. 2005; 19(10): 2591-2602.

79. Malard R, Rizvi M, Saleh A, Eldousset F, Elmaghraby M, El-Hennawi A, et al. A novel mutation in the FSH receptor gene associated with premature ovarian failure and polycystic ovary syndrome. Horm Metab Res. 2001; 33(4): 198-201.

80. Woad KJ, Prendergast D, Winship IM, Shelling AN. FSH receptor gene variants are rarely associated with premature ovarian failure. J Clin Endocrinol Metab. 2001; 86(5): 1958-1962.

81. Toleda SP, Brunner HG, Kraaij R, Post M, Daha PL, Hayashida CY, et al. An inactivating mutation of the luteinizing hormone receptor causes amenorrhea in a 46, XX female. J Clin Endocrinol Metab. 1996; 81(11): 3850-3854.

82. Puett D, Angelova K, da Costa MR, Warrenfeltz SW, Fanelli F. The luteinizing hormone receptor: insights into structure-function relationships and hormone-receptor mediated changes in gene expression in ovarian cancer cells. Mol Cell Endocrinol. 2010; 329(1-2): 47-55.

83. Ohkubo M, Yabu T, Yamashita M, Shimizu A. Molecular cloning of two gonadotropin receptors in mummichog Fundulus heteroclitus and their gene expression during follicular development and maturation. Gen Comp Endocrinol. 2013; 184: 75-86.

84. Wei S, Chen S, Gong Z, Ouyang X, An L, Xie K, et al. Alaralin active immunization influences expression levels of GnRHR, FSHR and LHR proteins in the ovary and enhances follicular development in ewes. Anim Sci J. 2013; 84(6): 466-475.

85. Conway GS, Conway E, Walker C, Hoppner W, Gromoll J, Simoni M. Mutation screening and isoform prevalence of the follicle stimulating hormone receptor gene in women with premature ovarian failure, resistant ovary syndrome and polycystic ovary syndrome. Clin Endocrinol (Oxf). 1999; 51(1): 97-99.

86. Sundblad V, Chiauzzi VA, Escobar ME, Dain L, Charreau EH. Screening of FSH receptor gene in Argentine women with premature ovarian failure, resistant ovary syndrome and high end of the normal range for FSH. Fertil Steril. 2001; 75(3): 535-539.

87. Constaneda I. Knockout of luteinizing hormone receptor abolishes the effects of follicle-stimulating hormone on preovulatory maturation and ovulation of mouse graafian follicles. Mol Endocrinol. 2005; 19(10): 2591-2602.

88. Malard R, Rizvi M, Saleh A, Eldousset F, ElMaghraby M, El-Hennawi A, et al. A novel mutation in the FSH receptor gene associated with premature ovarian failure, resistant ovary syndrome and high end of the normal range for FSH. Fertil Steril. 2001; 75(3): 535-539.

89. Woad KJ, Prendergast D, Winship IM, Shelling AN. FSH receptor gene variants are rarely associated with premature ovarian failure. Reprod Biomed Online. 2013; 26(4): 396-399.

90. Du J, Zhang W, Guo L, Zhang Z, Shi H, Wang J, et al. Two FSHR variants, haplotypes and meta-analysis in Chinese women with premature ovarian failure and polycystic ovary syndrome. Mol Genet Metab. 2010; 100(3): 292-295.

91. Uhlenhaut NH, Treier M, Fox2 function in ovarian development. Mol Genet Metab. 2006; 88(3): 225-234.

92. Plesarska MD, Bae J, Klein C, Hsieh AJ. Forkhead 2 is
expressed in the ovary and represses the promoter activity of the steroidogenic acute regulatory gene. Endocrinology. 2004; 145(7): 3424-3433.

91. Schmidt D, Ovitt CE, Anlag K, Fehsenfeld S, Gredsted L, Treier AC, et al. The murine winged-helix transcription factor FOXL2 is required for granulosa cell differentiation and ovary maintenance. Development. 2004; 131(4): 933-942.

92. Mu WJ, Wen HS, He F, Li JF, Liu M, Zhang YQ, et al. Cloning and expression analysis of follicle-stimulating hormone and luteinizing hormone receptor during the reproductive cycle in Korean rockfish (Sebastes schlegelii). Fish Physiol Biochem. 2003; 29(2): 287-298.

93. Chatterjee S, Modi D, Maitra A, Kadam S, Patel Z, Gokral J, et al. Screening for FOXL2 gene mutations in women with premature ovarian failure: an Indian experience. Reprod Biomed Online. 2007; 15(5): 554-560.

94. Bodega B, Porta C, Crosignani PG, Ginelli E, Marozzi A. Mutations in the coding region of the FOXL2 gene are not a major cause of idiopathic premature ovarian failure. Mol Hum Reprod. 2004; 10(8): 555-557.

95. Ni F, Wen Q, Wang B, Zhou S, Wang J, Mu Y, et al. Mutation analysis of FOXL2 gene in Chinese patients with premature ovarian failure. Gynecol Endocrinol. 2010; 26(4): 246-249.

96. Castrillon DH, Miao L, Kollipara R, Horner JW, DePinho RA. Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. Science. 2003; 301(5630): 215-218.

97. Gallardo TD, John GB, Bradshaw K, Weit C, Reijo-Pera R, Vogt PH, et al. Sequence variation at the human FOXO3 locus: a study of premature ovarian failure and primary amenorrhea. Hum Reprod. 2008; 23(1): 216-221.

98. Watkins WJ, Umbers AJ, Woad KJ, Harris SE, Winship IM, Gersak K, et al. Mutational screening of FOXL3A and FOXL1A in women with premature ovarian failure. Fertil Steril. 2006; 85(4): 1516-1521.

99. Vinci G, Christin-Maitre S, Pasquier M, Bouchard P, Felsou M, Veitia RA. FOXL3A variants in patients with premature ovarian failure. Clin Endocrinol (Oxf). 2008; 68(3): 495-497.

100. Kutlaris EM, Papanikolaou EG, Fatemi HM, Devroe P. Estrogen and folliculogenesis: is one necessary for the other?. Curr Opin Obstet Gynecol. 2005; 17(3): 249-253.

101. Bretherick KL, Hanna CW, Currie LM, Flucker MR, Hammond GL, Robinson WP. Estrogen receptor alpha gene polymorphisms are associated with idiopathic premature ovarian failure. Fertil Steril. 2008; 89(2): 318-324.

102. Yoon SH, Choi YM, Hong MA, Lee GH, Kim JJ, Im HJ, et al. Estrogen receptor α gene polymorphisms in patients with idiopathic premature ovarian failure. Hum Reprod. 2010; 25(1): 283-287.

103. Yang JJ, Cho PY, Lim YJ, Ko KP, Lee KS, Kim H, et al. Estrogen receptor-1 genetic polymorphisms for the risk of premature ovarian failure and early menopause. J Women’s Health (Larchmt). 2010; 19(2): 297-304.

104. Cordts EB, Santos AA, Peluso C, Bianco B, Barbosa CP, Christofolini DM. Risk of premature ovarian failure is associated with the Pvull polymorphism at estrogen receptor gene ESR1. J Assist Reprod Genet. 2012; 29(12): 1421-1425.

105. Albagha OM, Pettersson U, McCartney FE, MacDonald HM, Reid DM, et al. Association of oestrogen receptor alpha gene polymorphisms with postmenopausal bone loss, bone mass, and quantitative ultrasound properties of bone. J Med Genet. 2005; 42(3): 240-246.

106. Pouresmaeil F, Roohi A, Tehrani MJ, Azarghazh E, Kazemi B, Tehrani HS, et al. Osteoporosis and its Association with Estrogen Receptor alpha Gene Polymorphism in a popula-
123. Marozzi A, Manfredini E, Tibiletti MG, Furlan D, Villa N, Vegetti W, et al. Molecular definition of Xq common-delet ed region in patients affected by premature ovarian failure. Hum Genet. 2000; 107(4): 304-311.

124. Bione S, Sala C, Manzini C, Arrigo G, Zuffardi O, Banfi S, et al. A human homologue of the Drosophila melanogaster diaphanous gene is disrupted in a patient with premature ovarian failure: evidence for conserved function in oogenesis and implications for human sterility. Am J Hum Genet. 1998; 62(3): 533-541.

125. Mandon-Pépin B, Oustry-Vaiman A, Vigier B, Piumi F, Criqui MH, Ohtsuka J, et al. Profiles and chromosomal localization of genes controlling meiosis and follicular development in the sheep ovary. Biol Reprod. 2003; 68(3): 985-995.

126. Jiang R, Dong J, Joo J, Geller NL, Zheng G. Simple strategies for haplotype analysis of the X chromosome with application to age-related macular degeneration. Eur J Hum Genet. 2011; 19(7): 801-806.

127. Laanepere M, Aitman T, Stavreus-Evers A, Nilsson TK, Yngve A, Salumets A. Folate-mediated one-carbon metabolism and its effect on female fertility and pregnancy viability. Folate-mediated one-carbon metabolism and its effect on female fertility and pregnancy viability. Nutr Rev. 2010; 68(2): 99-113.

128. Rah H, Jeon YJ, Choi Y, Shim SH, Yoon TK, Choi DH, et al. Association of methylenetetrahydrofolate reductase (MTHFR 677C>T) and thymidylate synthase (TS and TS 1494del6) polymorphisms with premature ovarian failure in Korean women. Maturitas. 2012; 71: 402-406.

129. Rosen MP, Shen S, McCulloch CE, Rinaudo PF, Cedars MI, Dobson AT. Methylenetetrahydrofolate reductase (MTHFR) is associated with ovarian follicular activity. Fertil Steril. 2007; 88(3): 632-638.

130. Lee VH, Britt JH, Dunbar BS. Localization of laminin proteins during early follicular development in pig and rabbit ovaries. J Reprod Fertil. 1996; 108(1): 115-122.

131. Irving-Rodgers HF, Rodgers RJ. Extracellular matrix in ovarian follicular development and disease. Cell Tissue Res. 2005; 322(1): 89-98.

132. Pyun JA, Chab DH, Kwacka KB. LAMC1 gene is associated with premature ovarian failure. Maturitas. 2012; 71: 402-406.

133. Juanich A, Le Cam A, Montfort J, Guiguen Y, Bobe J. Identification of differentially expressed miRNAs and their potential targets during fish ovarian development. Bilo Reprod. 2013; 89(5): 128.

134. Donadeu FX, Schauer SN, Sontakke SD, Inbar Y, et al. Identification of miRNAs in ovarian follicular and luteal development. J Endocrinol. 2012; 215(3): 323-334.

135. Hossain MM, Sohel MM, Schellander K, Tesfaye D. Characterization and importance of microRNAs in mammalian gonadal functions. Cell Tissue Res. 2012; 349(3): 679-690.

136. Yang X, Zhou Y, Peng S, Wu L, Lin HY, Wang S, et al. Differentially expressed plasma microRNAs in premature ovarian failure patients and the potential regulatory function of mir-23a in granulosa cell apoptosis. Reproduction. 2012; 144(2): 235-244.

137. McBride D, Carré W, Sontakke SD, Hogg CO, Law A, Donadeu FX, et al. Identification of miRNAs associated with the follicular-luteal transition in the ruminant ovary. Reproduction. 2012; 144(2): 221-233.

138. Thomson T, Lin H. The biogenesis and function of PIWI proteins and piRNAs: progress and prospect. Annu Rev Cell Dev Biol. 2009; 25: 355-376.

139. Lei L, Jin S, Gonzalez G, Behringer RR, Woodruff TK. The regulatory role of Dicer in folliculogenesis in mice. Mol Cell Endocrinol. 2010; 318(1-2): 63-73.

140. Murchison EP, Stein P, Xuan Z, Pan H, Zhang MQ, Schultz RM, et al. Critical roles for Dicer in the female germline. Genes Dev. 2007; 21: 682-693.

141. Otsuka M, Zheng M, Hayashi M, Lee JD, Yoshino O, Lin S, Han J. Impaired microRNA processing causes corpus luteum insufficiency and infertility in mice. J Clin Invest. 2008; 118: 1944-1954.

142. Hong X, Luense LJ, McGinnis LK, Nothick WB, Christenson LK. Dicer1 is essential for female fertility and normal development of the follicle-reproductive system. Endocrinol. 2008; 149(12): 6207-6212.

143. Nagaraja AK, Andreu-Vieyra C, Franco HL, Ma L, Chen R, Han DY, et al. Deletion of Dicer in somatic cells of the female reproductive tract causes sterility. Mol Endocrinol. 2008; 22: 2336-2352.

144. Friedler SD, Carletti MZ, Hong X, Christenson LK. Hormonal regulation of MicroRNA expression in periovulatory mouse mural granulosa cells. Biol Reprod. 2008; 79(6): 1030-1037.

145. Yao N, Yang BO, Liu Y, Tan XY, Lu CL, Yuan XH, et al. Follicle-stimulating hormone regulation of microRNA expression on progesterone production in cultured rat granulosa cells. Endocrinol. 2010; 38(2): 158-166.

146. McGuire MM, Bowden W, Engel NJ, Ahn WW, Kovance E, Rajkovic A. Genomic analysis using high-resolution single-nucleotide polymorphism arrays reveals novel microdeletions associated with premature ovarian failure. Fertil Steril. 2011; 95(5): 1595-1600.

147. Bolou-Filas E, Hall E, Speed R, Taggart M, Grey C, de Massy B, et al. Mutation of the mouse Sycp1 gene disrupts synapsis and suggests a link between synaptonemal complex structural components and DNA repair. PLoS Genet. 2009; 5(2): e1000393.

148. Christin-Maitre S, Tachdjian G. Genome-wide association study and premature ovarian failure. Ann Endocrinol (Paris). 2010; 71(3): 218-221.

149. Qin Y, Sun M, You L, Wei D, Sun J, Liang X, et al. ESR1, HK3 and BRSK1 gene variants are associated with both age at natural menopause and premature ovarian failure. Orphanet J Rare Dis. 2012; 7: 5.

150. Maclaran K, Panay N. Premature ovarian failure. J Fam Plann Reprod Health Care. 2011; 37: 35-42.

151. Tehrani FR, Solaymani-Dodaran M, Tohid M, Gohari MR, Azizi F. Modeling age at menopause using serum concentration of anti-mullerian hormone. J Clin Endocrinol Metab. 2013; 98(2): 729-735.

152. Meduri G, Massin N, Guibourdenche J, Bachelot A, Fiori O, Kutten F, et al. Serum anti-Mullerian hormone expression in women with premature ovarian failure. Hum Reprod. 2007; 22(1): 117-123.

153. Edassery SL, Shatavi SV, Kunkel JP, Hauer C, Brucker C, Penumatsa K, et al. Autoantigens in ovarian autoimmunity associated with unexplained infertility and premature ovarian failure. Hum Reprod Update. 2010; 16(5): 683-701.

154. Park C, Overton C. Premature menopause linked to CVD and osteoporosis. Practitioner. 2010; 254(1727): 21-22.

155. Deeks AA, Gibson-Helm M, Teede H, Vincent A. Premature menopause: a comprehensive understanding of psychological aspects. Climacteric. 2011; 14(5): 565-572.

156. Liu T, Huang Y, Guo L, Cheng W, Zou G. CD44+/CD105+ human amniotic fluid mesenchymal stem cells survive Premature Ovarian Failure Genetics
and proliferate in the ovary long-term in a mouse model of chemotherapy-induced premature ovarian failure. Int J Med Sci. 2012; 9(7): 592-602.

159. Sinchak K, Wagner EJ. Estradiol signaling in the regulation of reproduction and energy balance. Front Neuroendocrinol. 2012; 33(4): 342-363.

160. Song JY, Siegfried JM, Diergaard B, Land SR, Bowser R, Stabile LP, et al. Genetic variation in ESR2 and estrogen receptor-beta expression in lung tumors. Cancer Epidemiol. 2013; 37(4): 518-522.

161. Kauffman EC, Robinson BD, Downes M, Marcinkiwicz K, Vourganti S, Scherr DS, et al. Estrogen receptor-β expression and pharmacological targeting in bladder cancer. Oncol Rep. 2013; 30(1): 131-138.

162. Yoon SH, Choi YM, Hong MA, Kim JJ, Im HJ, Lee GH, et al. Inhibin α gene promoter polymorphisms in Korean women with idiopathic premature ovarian failure. Hum Reprod. 2012; 27(6): 1870-1873.

163. Qin Y, Zhao H, Xu J, Shi Y, Li Z, Qiao J, et al. Association of 8q22.3 locus in Chinese Han with idiopathic premature ovarian failure (POF). Hum Mol Genet. 2012; 21(2): 430-436.

164. Oldenburg RA, van Dooren MF, de Graaf B, Simons E, Govaerts L, Swagemakers S, et al. A genome-wide linkage scan in a Dutch family identifies a premature ovarian failure susceptibility locus. Hum Reprod. 2008; 23(12): 2835-2841.